Harold J. Burstein
#124,322
Most Influential Person Now
Harold J. Burstein's AcademicInfluence.com Rankings
Harold J. Bursteinphilosophy Degrees
Philosophy
#5761
World Rank
#8654
Historical Rank
Logic
#2980
World Rank
#4068
Historical Rank
Download Badge
Philosophy
Why Is Harold J. Burstein Influential?
(Suggest an Edit or Addition)Harold J. Burstein's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY (2019) (3673)
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 (2013) (2859)
- American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. (2005) (1736)
- American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. (2002) (1006)
- Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. (2010) (924)
- Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinoma (2003) (687)
- Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. (2014) (671)
- Use of alternative medicine by women with early-stage breast cancer. (1999) (663)
- De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 (2018) (639)
- Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. (2020) (615)
- Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. (2014) (612)
- Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. (2008) (571)
- Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. (2012) (535)
- American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. (2010) (524)
- Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. (2014) (510)
- Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. (2010) (503)
- Breast cancer. Clinical practice guidelines in oncology. (2009) (498)
- Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. (2015) (483)
- Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. (2008) (481)
- Adjuvant ovarian suppression in premenopausal breast cancer. (2015) (467)
- The distinctive nature of HER2-positive breast cancers. (2005) (453)
- Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. (2008) (439)
- Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. (2018) (426)
- Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline. (2016) (424)
- Ductal carcinoma in situ of the breast. (2004) (398)
- Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. (2001) (376)
- Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. (2003) (359)
- Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. (2008) (358)
- American society of clinical oncology clinical practice guideline update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. (2010) (354)
- De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. (2018) (353)
- Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer (2018) (348)
- NCCN Guidelines Insights: Breast Cancer, Version 1.2017. (2017) (344)
- Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer. (2001) (327)
- Invasive breast cancer version 1.2016 (2016) (307)
- Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. (2019) (294)
- Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. (2003) (291)
- Quality of non-breast cancer health maintenance among elderly breast cancer survivors. (2003) (283)
- NCCN Guidelines Insights Breast Cancer, Version 1.2016. (2015) (281)
- Estimating the Benefits of Therapy for Early Stage Breast Cancer The St Gallen International Consensus Guidelines for the Primary Therapy of Early Breast Cancer 2019. (2019) (271)
- Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium (2020) (270)
- Congestive heart failure risk in patients with breast cancer treated with bevacizumab. (2011) (268)
- Docetaxel administered on a weekly basis for metastatic breast cancer. (2000) (267)
- Predictors of Resistance to Preoperative Trastuzumab and Vinorelbine for HER2-Positive Early Breast Cancer (2007) (249)
- Primary care for survivors of breast cancer. (2000) (236)
- Use of the Peroxisome Proliferator-Activated Receptor (PPAR) γ Ligand Troglitazone as Treatment for Refractory Breast Cancer: A Phase II Study (2003) (229)
- Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression. (2016) (228)
- Adjuvant chemotherapy in older women with early-stage breast cancer. (2009) (220)
- Trastuzumab plus vinorelbine or taxane chemotherapy for HER2‐overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study (2007) (219)
- NCCN task force report: management of neuropathy in cancer. (2009) (212)
- HER2 testing in breast cancer: NCCN Task Force report and recommendations. (2006) (205)
- Breast cancer, version 3.2013: featured updates to the NCCN guidelines. (2015) (204)
- American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays. (2004) (199)
- Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. (2014) (198)
- A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. (2008) (198)
- Breast Cancer, Version 3.2013 (2013) (193)
- Past, present, and future challenges in breast cancer treatment. (2014) (191)
- American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. (2002) (189)
- Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. (2019) (183)
- Breast cancer version 3.2014. (2014) (180)
- Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. (2016) (176)
- Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021 (2021) (175)
- Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival (2009) (172)
- The NCCN. Invasive breast cancer: Clinical practice guidelines in oncology™ (2007) (165)
- Breast cancer version 2.2015: Clinical practice guidelines in oncology (2015) (165)
- A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy (2008) (161)
- Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. (2009) (161)
- Aqueous antigens induce in vivo tolerance selectively in IL-2- and IFN-gamma-producing (Th1) cells. (1992) (159)
- Cardiac toxicity from systemic cancer therapy: a comprehensive review. (2010) (157)
- Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. (2019) (156)
- NCCN Guidelines Insights: Breast Cancer, Version 3.2018. (2019) (154)
- Aromatase inhibitor-associated arthralgia syndrome. (2007) (153)
- Breast Cancer Version 2.2015. (2015) (149)
- NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. (2006) (147)
- In vivo role of interleukin 4 in T cell tolerance induced by aqueous protein antigen (1993) (142)
- Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. (2005) (141)
- NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry. (2009) (139)
- VEGF as a Marker for Outcome Among Advanced Breast Cancer Patients Receiving anti-VEGF Therapy with Bevacizumab and Vinorelbine Chemotherapy (2008) (134)
- Invasive breast cancer. (2011) (133)
- American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays. (2011) (130)
- Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. (2015) (122)
- Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines. (2012) (120)
- Gemcitabine-induced radiation recall. (2002) (117)
- NCCN Guidelines® Insights: Breast Cancer, Version 4.2021. (2021) (111)
- NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer. (2007) (110)
- Surgery of the primary tumor does not improve survival in stage IV breast cancer (2011) (109)
- Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. (2021) (108)
- American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. (2002) (108)
- Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era. (2013) (107)
- Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. (2022) (106)
- Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. (2018) (98)
- Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis. (2005) (98)
- Side effects of chemotherapy. Case 1. Radiation recall dermatitis from gemcitabine. (2000) (97)
- Molecular origins of cancer. (2008) (93)
- Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial. (2016) (90)
- American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting. (2003) (89)
- Activation and Functions of CD4+ T‐Cell Subsets (1991) (86)
- Humoral immune functions in IL-4 transgenic mice. (1991) (84)
- Second consensus on medical treatment of metastatic breast cancer. (2007) (83)
- Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials. (2017) (83)
- Re: Pharmacogenomic Variation of CYP2D6 and the Choice of Optimal Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A Modeling Analysis (2008) (82)
- Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. (2017) (81)
- Do patients participating in clinical trials want to know study results? (2003) (81)
- Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer. (2023) (80)
- Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology. (2015) (80)
- Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. (2018) (79)
- Phase II study of SU11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC) (2005) (77)
- Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). (2014) (76)
- Discussing complementary therapies with cancer patients: what should we be talking about? (2000) (73)
- Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer. (2020) (72)
- Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced brea (2014) (71)
- Aromatase inhibitors and arthralgias: a new frontier in symptom management for breast cancer survivors. (2007) (68)
- Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. (2008) (68)
- Determining relevant biomarkers from tissue and serum that may predict response to single agent lapatinib in trastuzumab refractory metastatic breast cancer (2005) (67)
- Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. (2005) (66)
- Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. (2019) (66)
- Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. (2016) (61)
- Invasive breast cancer. (2007) (60)
- De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. (2019) (60)
- Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II–III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance) (2016) (59)
- Chemotherapy-related amenorrhea after adjuvant paclitaxel–trastuzumab (APT trial) (2015) (59)
- Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer. (2006) (57)
- NCCN Task Force Report: breast cancer in the older woman. (2008) (55)
- NCCN Task Force Report: mTOR inhibition in solid tumors. (2008) (52)
- Chemotherapy for metastatic breast cancer. (2007) (52)
- Bevacizumab for advanced breast cancer: all tied up with a RIBBON? (2011) (52)
- Breast Cancer, Version 3.2022 (2022) (52)
- New Combinations with Herceptin® in Metastatic Breast Cancer (2001) (51)
- Neratinib (HKI-272), an irreversible pan erbB receptor tyrosine kinase inhibitor: phase 2 results in patients with advanced HER2+ breast cancer. (2009) (50)
- Functional Decline and Resilience in Older Women Receiving Adjuvant Chemotherapy for Breast Cancer (2019) (50)
- Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer (2009) (50)
- SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer. (2010) (48)
- Contrary Effects of the Receptor Tyrosine Kinase Inhibitor Vandetanib on Constitutive and Flow-Stimulated Nitric Oxide Elaboration in Humans (2011) (47)
- Updated Survival Analysis of a Randomized Study of Lapatinib Alone or in Combination with Trastuzumab in Women with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab Therapy. (2009) (47)
- High performance teamwork training and systems redesign in outpatient oncology (2013) (47)
- Phase I study of Doxil and vinorelbine in metastatic breast cancer. (1999) (47)
- Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines? (2012) (46)
- Endocrine Treatment and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: ASCO Guideline Update (2021) (45)
- Seven-year (yr) follow-up of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC). (2017) (45)
- Cancer-related direct-to-consumer advertising: awareness, perceptions, and reported impact among patients undergoing active cancer treatment. (2009) (44)
- Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics (2012) (43)
- Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial. (2019) (42)
- Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial (2021) (41)
- HER2 overexpressing metastatic breast cancer (2002) (40)
- Novel agents and future directions for refractory breast cancer. (2011) (40)
- Corrections to "De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017". (2019) (38)
- Phase II, 3-arm study of CCI-779 in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer: preliminary results. (2004) (38)
- Highly Efficacious Nontoxic Preclinical Treatment for Advanced Metastatic Breast Cancer Using Combination Oral UFT-Cyclophosphamide Metronomic Chemotherapy (2007) (38)
- Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression Summary. (2016) (37)
- Abstract S1-04: A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC) (2013) (36)
- Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy. (2014) (34)
- Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03) (2021) (34)
- Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer. (2012) (34)
- Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions (2007) (34)
- The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early‐stage breast cancer (2006) (33)
- NCCN Guidelines® Insights: Breast Cancer, Version 4.2021. (2021) (32)
- Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer. (2011) (32)
- New cytotoxic agents and schedules for advanced breast cancer. (2001) (31)
- Nodal Irradiation after Breast-Cancer Surgery in the Era of Effective Adjuvant Therapy. (2015) (30)
- Correction to: De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 (Annals of Oncology (2017) 28(8) (1700–1712), (S0923753419321817), (10.1093/annonc/mdx308)) (2017) (29)
- Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice (2013) (29)
- CMF revisited in the 21st century. (2012) (28)
- Effect of treatment with sunitinib malate, a multitargeted tyrosine kinase inhibitor, on circulating plasma levels of VEGF, soluble VEGF receptors 2 and 3, and soluble KIT in patients with metastatic breast cancer. (2006) (28)
- Determinants of helper T cell-dependent antibody production. (1993) (27)
- Cognitive side-effects of adjuvant treatments. (2007) (27)
- Inadvertent use of aromatase inhibitors in patients with breast cancer with residual ovarian function: cases and lessons. (2006) (27)
- Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy. (2009) (27)
- Lymphopenia associated with adjuvant anthracycline/ taxane regimens. (2008) (26)
- Abstract GS1-05: TBCRC 033: A randomized phase II study of adjuvant trastuzumab emtansine (T-DM1) vs paclitaxel (T) in combination with trastuzumab (H) for stage I HER2-positive breast cancer (BC) (ATEMPT) (2020) (26)
- Patient advocates' role in clinical trials (2012) (25)
- Self-reported practices and attitudes of US oncologists regarding off-protocol therapy. (2008) (25)
- Clinical trial update: implications and management of residual disease after neoadjuvant therapy for breast cancer (2007) (25)
- Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study. (2013) (24)
- 397 Preoperative trastuzumab and vinorelbine (HN) is a well-tolerated, active regimen for Her2 3+/FISH+stage II/III breast cancer (2003) (24)
- On Sequencing the Full Genome of a Cancerous Cell (2009) (23)
- Endocrine Therapy for Hormone Receptor Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline Summary. (2016) (23)
- Chemotherapy for Triple-Negative Breast Cancer: Is More Better? (2016) (23)
- Local–regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial) (2019) (23)
- Trastuzumab regimens for HER2-overexpressing metastatic breast cancer. (2003) (23)
- Breast conservation following neoadjuvant therapy for breast cancer in the modern era: Are we losing the opportunity? (2016) (23)
- Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Joint analysis of IBCSG TEXT and SOFT trials. (2014) (22)
- LBA12 PALLAS: A randomized phase III trial of adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer (2020) (21)
- Concurrent Trastuzumab and Radiation Therapy (RT) in the Adjuvant Treatment of Breast Cancer (2005) (20)
- HER2 or not HER2: that is the question. (2005) (20)
- The role of angiogenesis inhibition in the treatment of breast cancer. (2006) (20)
- Pneumocystis carinii pneumonia during dose-dense chemotherapy for breast cancer. (2006) (19)
- Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy (2020) (18)
- Radiation therapy for ductal carcinoma in situ (2012) (18)
- Rebeccamycin analog for refractory breast cancer: A randomized phase II trial of dosing schedules (2006) (17)
- Practice Patterns, Guideline-Based Treatments, Costs and Efficacy of Care, and Global Perspectives: A Call for Papers on Excellence in Cancer Care (2010) (16)
- Experts' perspectives on the role of medical marijuana in oncology: A semistructured interview study (2017) (16)
- Novel approaches to advanced breast cancer: bevacizumab and lapatinib. (2007) (16)
- Estimation of tamoxifen metabolite concentrations in the blood of breast cancer patients through CYP2D6 genotype activity score (2012) (16)
- Adjuvant Therapy in Stage I Carcinoma of the Breast: The Influence of Multigene Analyses and Molecular Phenotyping (2012) (16)
- Blocking the Cycle: Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic, Hormone Receptor-Positive Breast Cancer. (2017) (15)
- Standards for follow-up care of patents with breast cancer. (2005) (15)
- Beyond tamoxifen--extending endocrine treatment for early-stage breast cancer. (2003) (14)
- Breast Cancer (2023) (14)
- Should response to preoperative chemotherapy affect radiotherapy recommendations after mastectomy for stage II breast cancer? (2012) (14)
- Neoadjuvant treatment strategies for HER2-positive breast cancer: cost-effectiveness and quality of life outcomes (2020) (14)
- Long-term follow-up after preoperative trastuzumab and chemotherapy for HER2-overexpressing breast cancer. (2015) (14)
- Serial analysis of circulating tumor cells in metastatic breast cancer receiving first-line chemotherapy. (2020) (14)
- Adjuvant Capecitabine in Triple-Negative Breast Cancer: New Strategies for Tailoring Treatment Recommendations. (2020) (13)
- The global landscape of treatment standards for breast cancer. (2021) (13)
- Patients with triple negative breast cancer: is there an optimal adjuvant treatment? (2013) (13)
- Consensus on Medical Treatment of Metastatic Breast Cancer (2003) (13)
- Deep time: the long and the short of adjuvant endocrine therapy for breast cancer. (2012) (13)
- Trastuzumab and vinorelbine or taxane chemotherapy for HER2+ metastatic breast cancer: The TRAVIOTA study. (2006) (13)
- Herceptin and vinorelbine for HER2-positive metastatic breast cancer : a phase II study (2000) (13)
- Treatment of early-stage human epidermal growth factor 2-positive cancers among medicare enrollees: age and race strongly associated with non-use of trastuzumab (2016) (13)
- Trastuzumab in Combination with Chemotherapy (2003) (12)
- JNCCN HER 2 Testing in Breast Cancer : NCCN Task Force Report and Recommendations (2006) (12)
- COVID-19 Pandemic Breast Cancer Consortium’s Considerations for Re-entry (2020) (12)
- Beaten at the Alamo by the Europeans. (2011) (12)
- Optimizing endocrine therapy in postmenopausal women with early stage breast cancer: A decision analysis for biological subsets of tumors (2005) (12)
- Breast Cancer Research and Treatment 2001 Reviewers (2004) (12)
- Making genuine progress against metastatic breast cancer. (2012) (12)
- Impact of neoadjuvant therapy on breast conservation rates in triple-negative and HER2-positive breast cancer: Combined results of CALGB 40603 and 40601 (Alliance). (2015) (11)
- T-cell-mediated activation of B cells. (1991) (11)
- Adjuvant hormonal therapy for early-stage breast cancer. (2010) (11)
- Could treatment with tamoxifen be superior to aromatase inhibitors in early-stage breast cancer after pharmacogenomic testing? A modeling analysis (2007) (11)
- Palbociclib after CDK and endocrine therapy (PACE): A randomized phase II study of fulvestrant, palbociclib, and avelumab for endocrine pre-treated ER+/HER2- metastatic breast cancer. (2018) (11)
- Molecular Testing in Breast Cancer. (2019) (10)
- Abstract S3-08: Randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Analysis of the SOFT trial (2015) (10)
- 215TiPPALLAS: PALbociclib CoLlaborative adjuvant study: A randomized phase 3 trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for HR+/HER2- early breast cancer (2017) (9)
- EMBRACE, eribulin, and new realities of advanced breast cancer (2011) (9)
- Breast cancer: noninvasive and special situations. (2010) (9)
- Avoiding Peg-Filgrastim Prophylaxis During the Paclitaxel Portion of the Dose-Dense Doxorubicin-Cyclophosphamide and Paclitaxel Regimen: A Prospective Study (2020) (9)
- Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial) (2021) (9)
- What is a patient navigator, and should we have them in major cancer centers? (2009) (9)
- Dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2/neu-positive breast cancer is not feasible due to excessive diarrhea: updated results. (2009) (8)
- Can Axillary Node Dissection Be Omitted in a Subset of Patients with Low Local and Regional Failure Rates? (2012) (8)
- Abstract PD05-01: CALGB 40302: Fulvestrant with or without Lapatinib as Therapy for Hormone Receptor Positive Advanced Breast Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Study (2010) (8)
- Abstract OT3-05-11: Palbociclib after CDK inhibitor and endocrine therapy (PACE): A randomized phase II study of fulvestrant versus palbociclib plus fulvestrant, with and without avelumab, for CDK inhibitor pre-treated HR+/HER2- metastatic breast cancer (2018) (8)
- Breast Cancer—Translational Therapeutic Strategies (2007) (8)
- A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma. (2019) (8)
- Hormone Replacement Therapy after Breast Cancer? (2003) (7)
- Off-label use of oncology drugs: too much, too little, or just right? (2013) (7)
- Postmenopausal breast cancer: a best endocrine strategy? (2015) (7)
- Circulating tumor cells in HER-2 positive metastatic breast cancer patients treated with trastuzumab and chemotherapy. (2009) (7)
- Abstract S3-09: Patient-reported endocrine symptoms, sexual functioning and quality of life (QoL) in the IBCSG SOFT trial: Adjuvant treatment with tamoxifen (T) alone versus tamoxifen plus ovarian function suppression (OFS) in premenopausal women with hormone receptor-po (2015) (7)
- A pilot study of adjuvant bevacizumab and chemotherapy after neoadjuvant chemotherapy for high-risk breast cancer (2008) (7)
- Adjuvant palbociclib (P) plus endocrine therapy (ET) for hormone receptor positive (HR+) breast cancer: A phase II feasibility study. (2014) (6)
- Time trends in the use of adjuvant chemotherapy (CTX) and outcomes in women with T1N0 breast cancer (BC) in the National Comprehensive Cancer Network (NCCN) (2013) (6)
- A Phase II Feasibility Study of Palbociclib in Combination with Adjuvant Endocrine Therapy for Hormone Receptor Positive Invasive Breast Carcinoma. (2019) (6)
- A pilot study of adjuvant bevacizumab after neoadjuvant chemotherapy for high-risk breast cancer (2007) (6)
- Dose-dense nab-paclitaxel (nanoparticle albumin-bound paclitaxel) in adjuvant chemotherapy for breast cancer: A feasibility study (2007) (6)
- Patients with anti-HER2 responsive disease: definition and adjuvant therapies. (2011) (6)
- Abstract P2-13-02: Chemotherapy-related amenorrhea (CRA) after adjuvant trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT trial) (2020) (6)
- Follow-up care of breast cancer survivors. (2003) (6)
- Cardiovascular safety of adjuvant bevacizumab for breast cancer. (2010) (6)
- Avastin for breast cancer, 2005-2011: requiescat in pacem? (2011) (5)
- Biosimilar Therapy for ERBB2 (HER2)-Positive Breast Cancer: Close Enough? (2017) (5)
- Perinephritic Abscess: Review of a Series of Cases1 (1931) (5)
- Adjuvant endocrine therapy for postmenopausal women: Type and duration. (2015) (5)
- Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial (2022) (5)
- Multidisciplinary considerations in the treatment of triple‐negative breast cancer (2020) (5)
- Unusual aspects of breast cancer: case 2. Synchronous bilateral lung and breast cancers. (2001) (5)
- Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03) (2022) (5)
- Adjuvant Endocrine Therapy (2010) (4)
- Local therapy outcomes and toxicity from the (anonymized for review) trial: A phase II randomized trial of adjuvant trastuzumab emtansine vs. paclitaxel in combination with trastuzumab in women with stage I HER2-positive breast cancer (2022) (4)
- Avastin, ODAC, and the FDA: are we drafting the right players? (2010) (4)
- Expanding Criteria for Prognostic Stage IA in Hormone Receptor-Positive Breast Cancer. (2021) (4)
- TBCRC 012: ABCDE, a phase II randomized study of adjuvant bevacizumab, metronomic chemotherapy (CM), diet and exercise after preoperative chemotherapy for breast cancer. (2010) (4)
- Preoperative trastuzumab (T) and paclitaxel (P) for HER2-overexpressing (HER2+) stage breast cancer (2001) (4)
- Optimizing Adjuvant Chemotherapy and Surgery for Early- and Late-Stage Breast Cancer. (2016) (4)
- Do clinical trials belong in clinical guidelines? (2009) (4)
- Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib? (2021) (4)
- Abstract OT1-03-21: PALLAS: PAlbociclib Collaborative Adjuvant Study: A randomized phase 3 trial of palbociclib with adjuvant endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer (2016) (4)
- Lou Gehrig, Angelina Jolie, and cancer genetics. (2013) (4)
- Quality measures, clinical practice, NCCN, and McAllen, Texas. (2009) (3)
- JNCCN NCCN Task Force Report : PET / CT Scanning in Cancer (2007) (3)
- Physical Activity, Weight, and Outcomes in Patients Receiving Chemotherapy for Metastatic Breast Cancer (C40502/Alliance) (2021) (3)
- Abstract PD10-02: Patient reported outcomes from the adjuvant trastuzumab emtansine (T-DM1) vs. paclitaxel + trastuzumab (TH) (ATEMPT) trial (TBCRC 033) (2020) (3)
- Improving tolerance of AIs: predicting risk and uncovering mechanisms of musculoskeletal toxicity. (2008) (3)
- Personalizing treatment in early-stage breast cancer: The role of standard clinical factors and genomic information in adjuvant chemotherapy decision making. (2009) (3)
- Duration of adjuvant trastuzumab: might less be more? (2018) (3)
- Abstract P3-11-01: Treatment patterns for young women with HR+/HER2- metastatic breast cancer in the United States in the era of CDK 4/6 inhibitors (2018) (3)
- Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al. (2017) (3)
- A "shot heard 'round the world" on cancer drug costs? (2012) (3)
- Preoperative Therapy as a Model for Translational Research in Breast Cancer (2008) (2)
- Use and duration of chemotherapy (CT) in patients (pts) with metastatic breast cancer (MBC) according to tumor subtype (TS) and line of therapy (tx). (2012) (2)
- Abstract OT3-05-08: PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase 3 trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for HR+/HER2- early breast cancer (2018) (2)
- Rebeccamycin analog for refractory breast cancer: a randomized phase II trial (2004) (2)
- Hypertrophic osteoarthropathy. (1997) (2)
- The continuity of care checklist: a critical frontier in patient safety. (2011) (2)
- Personalized medicine and breast cancer care. (2009) (2)
- Take your medicine. (2011) (2)
- Prospective Study Testing a Simplified Paclitaxel Premedication Regimen in Patients with Early Breast Cancer (2021) (2)
- P2-18-02: Cardiac Outcomes of Patients on Adjuvant Weekly Paclitaxel (T) and Trastuzumab (H) for Node Negative, HER2 Positive Breast Cancer (BCA). (2011) (2)
- Choosing Treatments on the Basis of Cost: Can Clinicians Opt for Less Expensive Treatments? (2015) (2)
- A View Toward the Future (2008) (2)
- Abstract GS2-05: Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): update of the combined TEXT and SOFT trials (2022) (2)
- Update of the oxford overview: new insight and perspectives in the era of personalized medicine. (2012) (2)
- Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer. (2012) (2)
- Case records of the Massachusetts General Hospital. Case 25-2009. A 36-year-old woman with hormone-receptor-positive breast cancer. (2009) (2)
- Cardiac Outcomes of Patients on Adjuvant Weekly Paclitaxel and Trastuzumab for Node Negative, HER2 Positive Breast Cancer (2017) (2)
- Myeloid growth factor support for dose-dense adjuvant chemotherapy for breast cancer. (2006) (2)
- Adjuvant endocrine therapy in postmenopausal women: making treatment choices based on the magnitude of benefit. (2019) (2)
- Commentary on “Internet Usage Among Women with Breast Cancer: An Exploratory Study” (2000) (2)
- Long-term outcomes after neoadjuvant trastuzumab and chemotherapy for HER2+ breast cancer. (2011) (2)
- Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial. (2023) (2)
- OT3-02-04: TBCRC 012: ABCDE, a Phase II Randomized Study of Adjuvant Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise after Preoperative Chemotherapy for Breast Cancer. (2011) (2)
- Abstract PD5-06: Adjuvant palbociclib plus endocrine therapy for hormone receptor positive/HER2 negative breast cancer: A phase II feasibility study (2018) (2)
- Adjuvant ovarian suppression in premenopausal breast cancer | NOVA. The University of Newcastle's Digital Repository (2015) (2)
- Local-Regional Recurrence in Women with N0/N1mi, HER2-Positive Breast Cancer: Results from a Prospective Multi-institutional Study (The APT Trial) (2017) (1)
- Abstract P1-07-04: Physical activity, weight and outcomes in patients receiving first-line chemotherapy for metastatic breast cancer: Results from CALGB 40502 (Alliance) (2018) (1)
- Disclosing pharma payments to oncologists: what will we learn? (2012) (1)
- A Breath-Taking Diagnosis. (2019) (1)
- SPIKES for difficult conversations with cancer patients. (2009) (1)
- A phase II study of eribulin in patients with HER2-negative, metastatic breast cancer: Evaluation of efficacy, toxicity, and patient-reported outcomes. (2014) (1)
- Adapted Application of NCCN Clinical Practice Guidelines in Oncology in the Middle East and North Africa Region (2010) (1)
- Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer. (2019) (1)
- Texting the doctor. (2011) (1)
- Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT) (2022) (1)
- Fifty years of systemic therapy for breast cancer: from one size fits all to tailored therapy. (2014) (1)
- Gastrointestinal and Cardiovascular Safety Profiles of Neratinib Monotherapy in Patients with Advanced ErbB2-Positive Breast Cancer. (2009) (1)
- Abstract P3-10-13: Prognostic Value of Genomic Analysis after Neoadjuvant Chemotherapy for Breast Cancer (2010) (1)
- Weighing a dose-dense option for adjuvant chemotherapy and trastuzumab in early-stage breast cancer. (2008) (1)
- Peek before you treat? Is it a fantasy or reality? (2011) (1)
- 'ADVANCE' (a pilot trial) ADjuVANt chemotherapy in the elderly: Developing and evaluating lower-toxicity chemotherapy options for older patients with breast cancer. (2022) (1)
- Late effects of adjuvant systemic therapies in women diagnosed with breast cancer at a young age. (2009) (1)
- A look at current and potential treatment approaches for hormone receptor‐positive, HER2‐negative early breast cancer (2022) (1)
- Adjuvant palbociclib for ER+ breast cancer (PALLAS Trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13): A preplanned analysis of the stage IIA cohort (2022) (1)
- NCCN Breast Cancer Version 3 . 2014 Clinical Practice Guidelines in Oncology (2014) (1)
- A phase I study of vandetanib and metronomic chemotherapy in advanced breast cancer. (2009) (1)
- Is there a role for the oncotype DX breast recurrence score genomic assay in estrogen receptor-low positive breast cancer? (2022) (1)
- Caring for breast cancer survivors. (2013) (1)
- A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer (2020) (1)
- The fifth "C" is cost: highlights from ASCO 2011. (2011) (1)
- Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer. Reply. (2021) (1)
- Abstract P5-18-03: Clinicopathological features among patients with HER2-positive breast cancer with prolonged response to trastuzumab based therapy (2012) (1)
- Angiogenesis inhibitors in breast cancer (2008) (1)
- How Old is Too Old? Breast Cancer Treatment in Octogenarians (2018) (1)
- Updates in anti-HER2 combination therapy. (2008) (1)
- Abstract P6-11-09: Impact of tumor subtype on clinical features, treatment, and clinical outcomes among breast cancer patients with central nervous system disease (2013) (1)
- Factors associated with non use of adjuvant trastuzumab in older patients with HER2+ breast cancer. (2016) (1)
- Predicting the Risk of Axillary Nodal Metastases and Their Use in Selecting Breast Surgery Options (2009) (1)
- If the choices are all the same, why not prefer the less-expensive option? (2012) (1)
- Pathway-based oncology care: time for more transparency. (2012) (1)
- Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT (2022) (1)
- Decision analysis: Excision alone versus excision plus radiation therapy for ductal carcinoma in situ. (2010) (1)
- Clinical A ctivity o f T rastuzumab a nd V inorelbine i n Women W ith H ER2-Overexpress ing M etastatic B reast Cancer (2001) (0)
- Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial (2022) (0)
- PG 11.02 Endocrine therapy for post-menopausal patients: type and duration (2015) (0)
- Implementation of a team training program in the treatment of breast cancer patients. (2012) (0)
- Bathsheba's Breast: Women, Cancer and History (2002) (0)
- Keeping cancer patients out of the hospital at the end of life. (2013) (0)
- Targeted Therapy for Breast Cancer (2015) (0)
- Abstract GS3-06: GS3-06 Palbociclib After CDK4/6i and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-treated ER+/HER2- Metastatic Breast Cancer (2023) (0)
- Expert opinion vs guideline based care: the St. Gallen Case study. (2013) (0)
- Screening contretemps: the real issue in the mammogram guideline debate. (2009) (0)
- Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials (2022) (0)
- Expanding criteria for prognostic stage IA disease in HR+ breast cancer. (2020) (0)
- Abstract PD11-06: PD11-06 Circulating tumor DNA association with residual cancer burden after neoadjuvant therapy in triple negative breast cancer in TBCRC 030 (2023) (0)
- Comprar Targeted Therapies in Breast Cancer | PHD Harold Burstein | 9780199735679 | Oxford University Press (2011) (0)
- 50 Years of Advances in Breast Cancer Treatment: What Have We Learned? Where Are We Going? (2014) (0)
- American S ociety o f C linical O ncology T echnology A ssessment Working G roup U pdate: U se o f A romatase I nhibitors i n t he Adjuvant S etting (2003) (0)
- Breast cancer: Neoadjuvant bevacizumab treatment—signal or noise? (2012) (0)
- Examining clinician confidence in the management of breast cancer (BC) based on subtype. (2018) (0)
- Abstract P5-15-08: A phase 2 study of eribulin as early-line treatment for HER2- MBC: Evaluation of efficacy, toxicity, and patient-reported outcomes (2017) (0)
- Using Genomic Profiling to Guide Treatment Decisions for ER-Positive Breast Cancers (2019) (0)
- Abstract GS1-07: Adjuvant palbociclib in HR+/HER2- early breast cancer: Final results from 5,760 patients in the randomized phase III PALLAS trial (2022) (0)
- Introduction: Current and future approaches to chemotherapy in patients with resistant breast cancer. (2011) (0)
- Circulating Tumor Cells in Breast Cancer: Fiction or Reality? (2008) (0)
- Adjuvant endocrine therapy in postmenopausal women: Risk stratification, type and duration (2019) (0)
- Circulating Tumor Cells in HER-2 Positive Metastatic Breast Cancer Patients Treated with Trastuzumab and Chemotherapy (2009) (0)
- Live Blogging from ASCO 2009 (2009) (0)
- ASO Visual Abstract: Expanding Staging Criteria in T1–2N0 Hormone Receptor-Positive Breast Cancer Patients Enrolled in TAILORx (2022) (0)
- Selectivity and intake of SRD goats grazing dry season caatinga in Northeast Brazil. (1996) (0)
- Abstract PD9-01: Expanding downstaging criteria in AJCC pathologic prognostic staging using OncotypeDx Recurrence Score® assay in T1-2N0 hormone-receptor positive patients enrolled in the TAILORx trial (2022) (0)
- Postneoadjuvant treatment for triple-negative breast cancer (2022) (0)
- The Legacy of Professor Aron Goldhirsch. (2020) (0)
- Simplifying guidelines: we only need one adjuvant chemotherapy regimen for breast cancer. (2012) (0)
- The top five in oncology: where do we go from here? (2012) (0)
- Combination therapy with gefitinib and capecitabine in metastatic breast cancer (MBC): A phase I trial. (2016) (0)
- Original article Cognitive side-effects of adjuvant treatments (2007) (0)
- Session 11: Adjuvant systemic treatment for the individual patient I: Endocrine therapies: New aspects for old treatments (2015) (0)
- Adjuvant endocrine therapy for postmenopausal women with ER positive breast cancer: tailoring therapy based on tumors and patients (2017) (0)
- The role of patient advocates in clinical trials: Perspectives from investigators and advocates in the Cancer and Leukemia Group B (CALGB). (2010) (0)
- With better adjuvant therapy, does breast cancer stage still matter? (2015) (0)
- Abstract PD18-01: Adjuvant Trastuzumab Emtansine Versus Paclitaxel plus Trastuzumab for Stage I HER2+ Breast Cancer: 5-year results and correlative analyses from ATEMPT (TBCRC033) (2023) (0)
- Take Your Medicine (2011) (0)
- Recent advances in the treatment of breast cancer: highlights from the 2010 San Antonio Breast Cancer Symposium. (2011) (0)
- Breast cancer treatment in the era of individualized care. (2013) (0)
- S38 Late effects of systemic adjuvant therapies in women diagnosed with breast cancer at a young age (2009) (0)
- Pre-judging data: benchmarking clinical significance before study results are known. (2012) (0)
- Resisting a fundamentalist policy (2005) (0)
- Abstract PD18-02: Adjuvant Paclitaxel and Trastuzumab Trial (APT) for Node-Negative, Human Epidermal Growth Factor Receptor 2–Positive (HER2+) Breast Cancer: final 10-year analysis (2023) (0)
- Beyond the guidelines: Clinical investigators' (CI) self-reported use of genomic assays (GA) to assist in decision-making regarding use of neoadjuvant (NA) and adjuvant chemotherapy for patients (pts) with ER-positive/HER2-negative (ER+/HER2-) early breast cancer (BC). (2017) (0)
- Preliminary Summary of the Consensus Discussion (2013) (0)
- Expanding the Staging Criteria for T1-2N0 Hormone-Receptor Positive Breast Cancer Patients Enrolled in TAILORx (2022) (0)
- Anemia in cancer: update on studies of erythropoiesis-stimulating agents. (2007) (0)
- Unmet challenges in systemic therapy for early stage breast cancer (2021) (0)
- Board recertification. (2010) (0)
- Avoiding peg-filgrastim (Peg-F) prophylaxis during the paclitaxel (T) portion of the dose-dense (DD) doxorubicin-cyclophosphamide (AC)-T regimen: A prospective study. (2019) (0)
- Pathologic Complete Response with Docetaxel Neoadjuvant Therapy for Breast Cancer (2003) (0)
- Information Transparency in the Drug Approval Process. (2018) (0)
- Clonal Hematopoiesis in Older Patients with Breast Cancer Receiving Chemotherapy. (2023) (0)
- Implementation of team training in outpatient breast oncology. (2012) (0)
- Conflict of interest and oncology guidelines. (2008) (0)
- Perspective and Highlights from the 27th Annual Miami Breast Cancer Conference (2010) (0)
- Measuring hope: patient expectations of chemotherapy for advanced cancer. (2012) (0)
- Comprar Breast Cancer: Translational Therapeutic Strategies | Gary H. Lyman | 9780849374166 | Informa Healthcare (2007) (0)
- Reply to S. Mahesh (2012) (0)
- Rebeccamycin analog for refractory breast cancer: a randomized phase II trial. (2004) (0)
- Addressing oncology pharmacy & policy. (2010) (0)
- Book Review Great Feuds in Medicine: Ten of the Liveliest Disputes Ever By Hal Hellman. 237 pp. New York, John Wiley, 2001. $24.95. 0-471-34757-4 (2001) (0)
- Perinephritic Abscess: Review of a Series of Cases 1 1Read before the Chicago Urological Society, May 22, 1930. (1931) (0)
- Abstract ES09-1: Update on management of ER positive metastatic breast cancer (2013) (0)
- Colon cancer: the new breast cancer. (2009) (0)
- Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030 (2023) (0)
- Have we been down this road before? (2011) (0)
- Abstract P3-08-05: Chemotherapy-related amenorrhea on adjuvant paclitaxel-trastuzumab (APT trial) (2013) (0)
- Update of the Oxford Overview: New Insight and Perspectives in the Era of Personalized Medicine (2012) (0)
- Randomized Phase II Trial of Letrozole and Letrozole Plus Low-Dose Metronomic Oral Cyclophosphamide as Primary Systemic Treatment in Elderly Breast Cancer Patients (2007) (0)
- Invasive Breast CancerPractice Guidelines in Oncology (2011) (0)
- JNCCN reaches 10. (2012) (0)
- Escalation, De-escalation, Adaptation, Speciation, Customization: The New Approaches to Breast Cancer. (2023) (0)
- Highlights of the American Society of Clinical Oncology Annual Meeting 2005 13–17 May, 2005, Florida, USA (2005) (0)
- ASO Visual Abstract: Sentinel Lymph Node Biopsy Alone is Adequate for Chemotherapy Decisions in Postmenopausal Early-Stage, Hormone-Receptor-Positive, HER2-Negative Breast Cancer with 1-3 Positive Sentinel Lymph Nodes (2022) (0)
- Use of experimental therapy outside of clinical trials among U.S. oncologists. (2006) (0)
- Clinical Memoranda (1938) (0)
- Oncology teamwork. (2008) (0)
- Biological basis of breast cancer: an introduction. (2007) (0)
- Assuring access to academic cancer centers. (2012) (0)
- Lucky to be an oncologist. (2013) (0)
- Targeted Therapies in Breast Cancer (2010) (0)
- Quality o f N on-Breast C ancer H ealth M aintenance A mong Elderly B reast C ancer S urvivors (2003) (0)
- Sentinel Lymph Node Biopsy Alone is Adequate for Chemotherapy Decisions in Postmenopausal Early-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer with One to Three Positive Sentinel Lymph Nodes (2022) (0)
- Update in Hematology and Oncology: Evidence Published in 2015 (2016) (0)
- By the way, doctor. I've been having PET-CT scans to look for any growth or spread of previously removed tumors. Are they as reliable in detecting breast cancer as a regular mammogram? (2009) (0)
- Abstract P2-09-09: The effects of treatment-induced symptoms, depression and age on sexuality in premenopausal women with early breast cancer receiving adjuvant endocrine therapy (2017) (0)
- Re-engineering the cooperative groups. (2010) (0)
- Cancer-related direct-to-consumer advertising: awareness, perceived impact, and associated patient and provider behavior (2008) (0)
- Neoadjuvant pertuzumab: the exception that proves the rule? (2014) (0)
- JNCCN NCCN Task Force Report : Adjuvant Therapy for Breast Cancer — Clarification and Expansion of NCCN Clinical Practice Guidelines (2006) (0)
- Mind the gap. (2011) (0)
- Prevention of Covert COVID Iatrogenesis (2020) (0)
- The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer (2023) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Harold J. Burstein?
Harold J. Burstein is affiliated with the following schools:
